SERVICE 04

Insurance Listing

Reimbursement
Expanding the market is possible through insurance coverage.
Evidence of cost-effectiveness and clinical utility is required.
Business Activities
• Analysis of the Japanese health insurance system and design of product-specific insurance pricing roadmaps
• C1/C2 coverage strategy and analysis of the New Medical Technology Evaluation System
• Support for the health insurance reimbursement process and consultation with relevant authorities
• Preparation of insurance listing applications using economic data, clinical evidence, and academic society opinions
• Building academic and clinical evidence through collaboration with Japanese medical institutions and academic organizations

The structure of Japan’s health insurance system is as follows:

Reimbursement

Picture 1: Structure of Japan’s Health Insurance System (Created by JOMDD)

Under Japan’s health insurance system, the amount that medical institutions can claim as compensation for providing insured medical services is fixed, and this compensation is called the “medical fee.”
The medical fee is determined by the Minister of Health, Labour and Welfare based on the opinions of the Central Social Insurance Medical Council (Chuikyo), an advisory body to the Minister. In principle, medical fees are revised every two years.
The medical fee primarily refers to the “technical fee,” which is the remuneration for performing medical services. In addition to the technical fee, the prices of materials used in medical procedures are separately set as “specific health insurance medical materials” (special medical devices and consumables).

The classification of insurance in Japan is as follows:

A1 (Comprehensive)

 Evaluated comprehensively under existing medical fee items (e.g., sutures, venipuncture needles)

A2 (Specific Comprehensive)

 Evaluated comprehensively under specific existing medical fee items (e.g., ultrasound equipment and ultrasound examinations)

A3 (Existing Technology with Modifications)

 Evaluated under existing medical fee items for the technology using the product

B1 (Existing Functional Part)

 Evaluated according to existing functional categories, separately from technical fees (e.g., coronary stents, pacemakers)

B2 (Existing Functional Part with Modifications)

 Evaluated according to existing functional categories, separately from technical fees (including changes to the definitions of functional categories)

B3 (Time-Limited Improvement Addition)

 Evaluated by adding a time-limited improvement fee to existing functional categories

C1 (New Function)

 A new functional category is required,but the technology using it has already been evaluated (e.g., artificially processed joint implants)

C2 (New Function / New Technology)

 The technology using the product has not been previously evaluated(e.g., leadless pacemaker)

Note: B3, C1, and C2 are evaluation categories that require approval by the Central Social Insurance Medical Council (Chuikyo).

Source: Central Social Insurance Medical Council, Subcommittee on Health Insurance Medical Materials, “Review of the Health Insurance Medical Materials System (Part 1)” (September 20, 2023)

List of Services